JCNRJournal of Clinical and Nursing Research2208-36852208-3693Bio-Byword Scientific Publishing Pty. Ltd.10.26689/jcnr.v10i3.14398ArticleAnalysis of Reasons for Suspension of Drug Clinical Trials Between China and Other Countrieshttps://artdesignp.com/journal/JCNR/10/3/10.26689/jcnr.v10i3.14398HeJingwen,ZhangYurong,WangRuizhong20261032026-04-03Objective: To analyze the various reasons for the suspension of drug clinical trials, provide suitable solutions to reduce the incidence of such suspensions, prevent wastage of resources, and enhance the completion rate of clinical trials. Method: Relevant information on drug clinical trials suspended in China and other countries was retrieved from “Drug Clinical Trial Registration and Information Disclosure Platform” and “ClinicalTrials.gov”. Various factors were statistically summarized, comparing the reasons for clinical trial suspensions between China and other countries, and analyzing differences among groups in various classification variables, including indications, years, trial phases, and types of drugs. Result: A total of 323,248 drug clinical trials were conducted internationally, with a suspension rate of 0.48% (1,564/323,248). Within this dataset, China reported 377 suspended clinical trials, constituting 1.66% (377/22,703) of its total studies, while other countries conducted a total of 300,545 clinical trials, resulting in a suspension rate of 0.39% (1,187/300,545). The primary cause of suspension in various countries was attributed to issues related to sponsors and funding. Notably, there existed a statistically significant difference in the number of suspended trials between China and other countries (p < 0.05). Conclusion: During the research preparation phase, sponsors should meticulously assess the feasibility of clinical trials and exercise prudence in development decisions. The clinical trial protocol design must prioritize safety and scientific validity. Research teams should be equipped with emergency risk control measures, adhere to pertinent laws and regulations governing clinical trial, and ensure adequate management. Thus, drug clinical trials can only be conducted with high quality, thereby ensuring the progression of drug marketing.

Roland M, Torgerson D, 1998, Understanding Controlled Trials: What Are Pragmatic Trials?. BMJ, 316(7127): 285.

Kendrach M, Anderson H, 1998, Fundamentals of Controlled Clinical Trials and Basic Evaluation Techniques. Journal of Pharmacy Practice, 11(3): 163–180.

Kandi V, Vadakedath S, 2023, Clinical Trials and Clinical Research: A Comprehensive Review. Cureus, 15(2): e35077.

China National Medical Products Administration; National Health Committee, 2020, Good Clinical Practice.

China National Medical Products Administration, 2022, Guidelines for Research of Human Bioavailability and Bioequivalence of Innovative Drugs.

Clinical Trials Registration and Results Information Submission, 2016. Visited on 2025-12-21, https://www.ecfr.gov/current/title-42/part-11.

Clinical Holds and Requests for Modification, 2004. Visited on 2025-12-22, https://www.ecfr.gov/current/title-21/section-312.42.

Senderowicz A, 2010, Information Needed to Conduct First-in-Human Oncology Trials in the United States: A View from a Former FDA Medical Reviewer. Clinical Cancer Research, 16(6): 1719–1725.

Austin D, Hayford T, 2021, Research and Development in the Pharmaceutical Industry.

DiMasi J, Grabowski H, Hansen R, 2016, Innovation in the Pharmaceutical Industry: New Estimates of R&D Costs. Journal of Health Economics, 47: 20–33.

Prasad V, Mailankody S, 2017, Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval. JAMA Internal Medicine, 177(11): 1569–1575.

McKinsey & Company, 2024, Accelerating Clinical Trials to Improve Biopharma R&D Productivity, visited on 2025-12-26, https://www.findd.ai/papers/accelerating-clinical-trials-to-improve-biopharma-rd-productivity/.

Earls E, 2012, Clinical Trial Delays: America’s Patient Recruitment Dilemma. Visited on 2026-1-6,https://www.clinicaltrialsarena.com/features/featureclinical-trial-patient-recruitment/?cf-view.

Su X, Pang X, Zeng X, et al., 2021, Analysis of Suspension of Clinical Trials for Drug Registration in China. Frontiers in Pharmacology, 11: 598574.

Wonnacott K, Lavoie D, Fiorentino R, et al., 2008, Investigational New Drugs Submitted to the Food and Drug Administration That Are Placed on Clinical Hold: The Experience of the Office of Cellular, Tissue and Gene Therapy. Cytotherapy, 10(3): 312–316.

Sung N, Crowley W, Genel M, et al., 2003, Central Challenges Facing the National Clinical Research Enterprise. JAMA, 289(10): 1278–1287.

Gresham G, Meinert J, Gresham A, et al., 2020, Assessment of Trends in the Design, Accrual, and Completion of Trials Registered in ClinicalTrials.gov by Sponsor Type, 2000–2019. JAMA Network Open, 3(8): e2014682.

Morrow R, Mintzes B, Gray G, et al., 2022, Industry Sponsor Influence in Clinical Trial Reporting in Canada: A Qualitative Interview Study. Clinical Therapeutics, 44(3): 374–388.

Bhatt A, 2017, International Council for Harmonisation E6(R2) Addendum: Challenges of Implementation. Perspectives in Clinical Research, 8(4): 162–166.

Versavel S, Subasinghe A, Johnson K, et al., 2023, Diversity, Equity, and Inclusion in Clinical Trials: A Practical Guide from the Perspective of a Trial Sponsor. Contemporary Clinical Trials, 126: 107092.

Getz K, Wenger J, Campo R, et al., 2008, Assessing the Impact of Protocol Design Changes on Clinical Trial Performance. American Journal of Therapeutics, 15(5): 450–457.

Getz K, Stergiopoulos S, Short M, et al., 2016, The Impact of Protocol Amendments on Clinical Trial Performance and Cost. Therapeutic Innovation and Regulatory Science, 50(4): 436–441.

Sharma S, 2010, How to Become a Competent Medical Writer?. Perspectives in Clinical Research, 1(1): 33–37.

Patil K, Kumar C, Yao S, 2023, Peer Review of a Clinical Trial Protocol: Practical Tips for Regulatory Medical Writers, Clinicians, and Clinical Scientists. Medical Writing, 32: 20–27.

Ramanan M, Stolz A, Rooplalsingh R, et al., 2020, An Evaluation of the Quality and Impact of the Global Research Response to the COVID-19 Pandemic. Medical Journal of Australia, 213(8): 380–380.